Watson's Generic Revatio Receives FDA Approval

Watson Pharmaceuticals

today announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio^®.  Watson intends to begin shipping the product in the near future.  Revatio^® is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. For the 12 months ending September 30, 2012, Revatio^® tablets had total U.S. sales of approximately $339 million according to IMS Health data.